Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
-
Published:2024-05
Issue:
Volume:
Page:
-
ISSN:2152-2650
-
Container-title:Clinical Lymphoma Myeloma and Leukemia
-
language:en
-
Short-container-title:Clinical Lymphoma Myeloma and Leukemia
Author:
Chari AjaiORCID,
Krishnan Amrita,
Rasche Leo,
Ye Jing Christine,
Garfall Alfred,
Popat Rakesh,
Lipe Brea,
Qin Xiang,
Campagna Michela,
Masterson Tara,
Tomlinson Chalmer,
Hilder Brandi,
Tolbert Jaszianne,
Renaud Thomas,
Smit M. Damiette,
Gray Kathleen,
Kane Colleen,
Heuck Christoph,
van de Donk Niels W.C.J.
Reference70 articles.
1. Teclistamab in relapsed or refractory multiple myeloma;Moreau;N Engl J Med,2022
2. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management;Rajkumar;Am J Hematol,2020
3. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study;Usmani;Lancet,2021
4. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021
5. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma;San-Miguel;N Engl J Med,2023
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献